Special Focus Session

SF 20b - Lung cancer screening (LCS): how to report findings?

Lectures

1
Chairperson's introduction

Chairperson's introduction

03:00Marie-Pierre Revel, Paris / FR

2
Definition of positive, negative and indeterminate screening results

Definition of positive, negative and indeterminate screening results

18:00Mathias Prokop, Nijmegen / NL

3
Which additional findings should be reported?

Which additional findings should be reported?

18:00Annemiek Snoeckx, Zandhoven / BE

4
How to minimise the overdiagnosis risk

How to minimise the overdiagnosis risk

18:00Mario Silva, Parma / IT

5
Optimising lung cancer screening with AI

Optimising lung cancer screening with AI

18:00Colin Jacobs, Nijmegen / NL

6
Panel discussion: How can we minimise harm and maximise benefits from screening?

Panel discussion: How can we minimise harm and maximise benefits from screening?

15:00Panel discussion: How can we minimise harm and maximise benefits from screening?

3 min
Chairperson's introduction
Marie-Pierre Revel, Paris / France
18 min
Definition of positive, negative and indeterminate screening results
Mathias Prokop, Nijmegen / Netherlands
  1. To learn about the criteria for each screening result category.
  2. To learn how to minimise the recall rate.
  3. To understand the justification for different follow-up intervals.
18 min
Which additional findings should be reported?
Annemiek Snoeckx, Zandhoven / Belgium
  1. To understand the difference between incidental findings in diagnostic vs screening settings.
  2. To learn about the incidence and potential impact of true incidental findings.
  3. To explore the potential benefits of reporting opportunistic incidental findings (e.g. coronary artery calcification).
18 min
How to minimise the overdiagnosis risk
Mario Silva, Parma / Italy
  1. To understand the risk of overdiagnosis in secondary prevention LCS.
  2. To learn about the characterisation of specific findings and hurdles of overdiagnosis in LCS.
  3. To understand the systematic approach to minimise overdiagnosis.
18 min
Optimising lung cancer screening with AI
Colin Jacobs, Nijmegen / Netherlands
  1. To learn about the different types of AI systems that can benefit lung cancer screening programmes.
  2. To understand novel AI developments that assess the probability of malignancy of nodules and lung cancer risk of participants.
  3. To understand how AI can be integrated to optimise workflow in lung cancer screening.
15 min
Panel discussion: How can we minimise harm and maximise benefits from screening?

This session offers AI-generated subtitles.